Advicenne announces the launch of its new website

Paris, 30 May 2022 – 8.30 pm CET – Advicenne (Euronext Growth Paris ALDVI – FR0013296746), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal diseases, today announced the launch of its new website, www.advicenne.com.

Retour aux communiqués de presse

Back to press releases

Ouvrir le document

Open the file

Configuring cookies

Click on the arrows to view the content and find out more about each cookie

Reject all and access website Save my choices

Cookies required for the Website to operate

Always Enabled

These cookies are required for the Website to operate and cannot be deactivated in our system. You can configure your browser to block these cookies or send you an alert about their existence but we cannot save your cookie preferences. These cookies do not contain any personal identification information.

Cookie	Duration	Description
cli_user_preference	12 months	This Cookies is set by GDPR Cookie Consent plugin to save users preference of cookie consent
cookielawinfo-checkbox-necessary	12 months	This cookie is defined by the GDPR Cookie Consent plugin and records the user’s consent to "Necessary" category cookies.
cookielawinfo-checkbox-performance	12 months	This cookie is defined by the GDPR Cookie Consent plugin. The cookie is used to store the user’s consent to "Performance" category cookies.
CookieLawInfoConsent	12 months	This Cookies is set by GDPR Cookie Consent plugin to save users preference of cookie consent
pll_language	12 months	The pll _language cookie is used by Polylang to remember the language selected by the user when he comes back to visit again the website. This cookie is also used to get the language information when not available in another way.
viewed_cookie_policy	12 months	This cookie is defined by the GDPR Cookie Consent plugin and is used to store the user’s acceptance or rejection of cookies. It does not store any personal data.

Performance cookies

These enable us to assess how people use our Website. All information collected by these cookies is aggregated and anonymised. If you do not accept these cookies, we will not be informed about your visit to our Website..

Cookie	Duration	Description
_ga	6 months	Records a unique identifier used to generate statistical data on how people use our Website.
_ga_VQ7XH9070S	6 months	Used for reporting and distinguishing a user and to calculate visitor, session and campaign data for site analytics to optimize the services the website can offer.
_gat_gtag_UA_28487651_5	1 minute	Website ID code for tracking visits This cookie is deleted 1 minute after its creation.
_gid	1 day	Records a unique identifier used to generate statistical data on how people use our Website. This cookie is deleted 1 day after its creation.

Advicenne announces the launch of its new website

Latest news

Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103

Advicenne reports its First Half financial results as of June 30, 2024, and updates on its activities

Advicenne announces an 8.8% increase in gross sales for H1 2024 and provides an update on its activities

Advicenne announces the approval of all resolutions supported by the Board of Directors at its Combined General Meeting

Dernières Actualités

Advicenne franchit des étapes majeures aux Etats-Unis grâce à plusieurs opinions favorables de la FDA sur ADV7103

Advicenne présente ses résultats financiers semestriels au 30 juin 2024 et fait le point sur ses activités

Advicenne annonce une progression de 8,8% des ventes brutes au S1 2024 et fait le point sur ses activités

Advicenne annonce l’approbation de l’ensemble des résolutions soutenues par le Conseil d’administration lors de son assemblée générale mixte